US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Range Cancer Therapeutics ETF

9.02

0.0000

Volume:- -

Turnover:- -

Market Cap:7.04M

PE:23.74

High:9.02

Open:9.02

Low:9.02

Close:9.02

52wk High:9.02

52wk Low:9.02

Shares:780.81K

Float Shares:780.81K

Volume Ratio:- -

T/O Rate:- -

Dividend:0.00

Dividend Rate:0.01%

EPS(TTM):0.3800

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial

Lantern Pharma Raises Capital Through Recent Securities Offerings

MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy

Junshi Bio (01877) Surges Over 4% on Strategic Partnership with Meijie Medical to Explore "Multimodal Drug-Device Combination" in Cancer Treatment

Coiled Therapeutics Director Increases Stake as Precision Oncology Pipeline Advances

Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II

Gene Therapy Aiming to Cure Hepatitis B Enters Human Trials, Silencing the Virus Without Altering DNA

FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

5万治疗费背后，“毛孩子”的晚年谁来守护？宠物抗癌险应运而生

Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy

uniQure seeks accelerated approval for Huntington’s gene therapy

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

Circio boosts circVec gene therapy data and secures funding runway to 2030

Circio and Full Circles join forces on non-viral in vivo cell therapy platform

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/CNCR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","market":"US","secType":"STK","nameCN":"Range Cancer Therapeutics ETF","latestPrice":9.02,"timestamp":1790798400000,"preClose":9.02,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":780814,"shares":780814,"eps":0.38,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-30 16:00:00 EDT","open":9.02,"high":9.02,"low":9.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.38,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.02,"sharesOutstanding":780814,"nav":8.9,"aum":6949244.6,"dividendRate":0.000111,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","floatShares":780814,"roa":"--","roe":"--","lyrEps":0,"shares":780814,"dividePrice":0.001,"high":9.02,"amplitude":0,"preClose":9.02,"low":9.02,"week52Low":9.02,"pbRate":"--","week52High":9.02,"institutionHeld":0,"latestPrice":9.02,"eps":0.38,"divideRate":0.000111,"volume":0,"delay":0,"ttmEps":0.38,"open":9.02,"prevYearClose":9.02,"prevWeekClose":9.02,"prevMonthClose":9.02,"prevQuarterClose":9.02,"fiveDayClose":9.02,"twentyDayClose":9.02,"sixtyDayClose":9.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-28","symbol":"CNCR","reason":null,"defaultRemindTime":1748439000000,"announcedDate":"2025-05-27","type":"delisting","dateTimestamp":1748404800000},{"market":"US","date":"2021-12-29","symbol":"CNCR","amount":1.8533352,"defaultRemindTime":1640788200000,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000},{"market":"US","date":"2020-12-30","symbol":"CNCR","amount":0.2881193,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-01-04","payableDate":"2020-12-31","currency":"USD","type":"dividend","dateTimestamp":1609304400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNCR\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-30","recordDate":"2020-12-31","paymentDate":"2021-01-04","value":0.2881193,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":1.8533352,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNCR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNCR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672983731","title":"Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672983731","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672983731?lang=en_us&edition=fundamental","pubTime":"2026-10-01 12:18","pubTimestamp":1790828280,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an announcement. Arovella Therapeutics is advancing an iNKT cell therapy platform aimed at...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","GNOM","BK4585","BK4588","IBBQ","IBB","LFSC","LABX","FBT","ALA","TBXU","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672787807","title":"Lantern Pharma Raises Capital Through Recent Securities Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2672787807","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672787807?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:35","pubTimestamp":1790800509,"startTime":"0","endTime":"0","summary":"The latest update is out from Lantern Pharma ( ($LTRN) ). Lantern Pharma Inc., a clinical-stage, AI-native biopharma focused on precision oncology ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lantern-pharma-raises-capital-through-recent-securities-offerings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lantern-pharma-raises-capital-through-recent-securities-offerings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LTRN","CANC","VTHR","AIPO","BK4139","AGIX","CHAT","ARTY","QTOC","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671520485","title":"MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671520485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671520485?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:10","pubTimestamp":1790770233,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced that its clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell system within an Advance...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","GNOM","SYNB","TBXU","BK4585","BK4588","FBT","INKT","IBBQ","BK4139","IBB","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195660530","title":"Junshi Bio (01877) Surges Over 4% on Strategic Partnership with Meijie Medical to Explore \"Multimodal Drug-Device Combination\" in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1195660530","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195660530?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:50","pubTimestamp":1790736617,"startTime":"0","endTime":"0","summary":"Junshi Bio (01877) rose more than 4%, reaching 4.03% as of press time, at HK$19.09, with a turnover of HK$23.2684 million.On the news front, according to Junshi Bio's official WeChat account, the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0329678337.USD","01877","VXUS","06078","CANC","BK1515","CNCR","BK1209","159891","LU0737861772.HKD","BK4585","BK1583","LU2488822045.USD","LU0329678170.USD","KCAI","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670223375","title":"Coiled Therapeutics Director Increases Stake as Precision Oncology Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2670223375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670223375?lang=en_us&edition=fundamental","pubTime":"2026-09-28 17:37","pubTimestamp":1790588243,"startTime":"0","endTime":"0","summary":"An update from Roquefort Investments PLC ( ($GB:COIL) ) is now available. Coiled Therapeutics plc, an AIM-quoted precision oncology developer of fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/coiled-therapeutics-director-increases-stake-as-precision-oncology-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/coiled-therapeutics-director-increases-stake-as-precision-oncology-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CNCR","CANC","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669108132","title":"Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II","url":"https://stock-news.laohu8.com/highlight/detail?id=2669108132","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669108132?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:24","pubTimestamp":1790144664,"startTime":"0","endTime":"0","summary":"An update from Sensorion SAS ( ($FR:ALSEN) ) is now available. Sensorion has sharpened its strategic focus on SENS-601, a single-vector AAV gene th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","FBT","GNOM","SENS","TBXU","SYNB","BK4588","BK4585","BK4082","IBBQ","CNCR","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124333290","title":"Gene Therapy Aiming to Cure Hepatitis B Enters Human Trials, Silencing the Virus Without Altering DNA","url":"https://stock-news.laohu8.com/highlight/detail?id=1124333290","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124333290?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:05","pubTimestamp":1790078757,"startTime":"0","endTime":"0","summary":"This article interprets professional academic research and does not constitute medical advice. Hepatitis B is a stubborn virus that has proven extremely difficult to eliminate. Since American...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668991067","title":"FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668991067","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668991067?lang=en_us&edition=fundamental","pubTime":"2026-09-18 02:35","pubTimestamp":1789670130,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved Fayuvi, which it calls “the first treatment for pediatric patients with mucopolysaccharidosis type I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","GNOM","CNCR","LABU","FBT","SYNB","BK4588","BK4585","IBB","IBBQ","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936994","title":"Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936994?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594520,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestroc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","FBT","IDNA","BK4588","GDOC","TBXU","LGVN","CNCR","BK4585","GNOM","LFSC","MEDX","NVIB","SYNB","HYLG","BK4139","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667444786","title":"Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667444786","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667444786?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (\"Legend Biotech\" or the \"Company\"), a global leader in cell therapy, today announced that its Board of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","MEMS","GNOM","IBBQ","BK4585","XBI","LFSC","FBT","LEGN","BK4139","BK4505","BK4588","BK4581","CNCR","CANC","IBB","R","MEDI","SYNB","BK4232","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WDNA","HYLG","GNMX","PTH","HRTS","FBT","CURE","XPH","IBBQ","CANC","GPCR","MNTL","JHMH","PINK","FXH","IBRN","JDOC","LLYX","PBE","IBB","IBBJ","FHLC","SURI","BME","PSIL","GDOC","PSCH","RSPH","BBP","IDNA","NVIB","CNCR","GSKH","LFSC","FTXH","MRNY","PBPH","AZNH","SYNB","GNOM","PJP","IEIH","SBIO","MDTX","APXH","BIB","MEDX","TBXU","BBH","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665730023","title":"Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665730023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665730023?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:11","pubTimestamp":1788873063,"startTime":"0","endTime":"0","summary":"An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma has repositioned itself as a precision oncology-led biotech, m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","CNCR","MDCX","NVIB","BK4139","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MDTX","JDOC","JHMH","HYLG","PINK","SBIO","IBBJ","NVIB","FBT","BME","IBRN","PSCH","SURI","TBXU","GNOM","LLYX","PBPH","MEDX","APXH","IBB","GPCR","MRNY","PJP","SYNB","HRTS","WDNA","CURE","PBE","GDOC","PTH","BBH","GNMX","CNCR","FXH","FHLC","LFSC","AZNH","XPH","LENZ","MNTL","GSKH","FTXH","CANC","MEDI","RSPH","PSIL","BBP","IBBQ","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187149909","title":"5万治疗费背后，“毛孩子”的晚年谁来守护？宠物抗癌险应运而生","url":"https://stock-news.laohu8.com/highlight/detail?id=1187149909","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187149909?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868869,"startTime":"0","endTime":"0","summary":"今年8月底，赵先生的爱犬“旺财”被确诊为淋巴瘤。“那一刻，我下定决心要救治旺财，”赵先生回忆道。然而，当宠物医院递来一张超过5万元的治疗费用清单时，他心头还是猛地一紧。“与旺财相伴10余年，实在不忍心看它被恶性肿瘤折磨，”他无奈地表示。作为众安保险宠物险产品总监，李爽敏锐地注意到，在2015年至2019年间的“养宠爆发期”入手的宠物正陆续步入中老年阶段，肿瘤等老年犬猫高发疾病的诊疗需求随之激增。面...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","CANC","LU2488822045.USD","BK1209","LU0737861772.HKD","CNCR","LU0329678170.USD","06078","LU0329678337.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665101723","title":"Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665101723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665101723?lang=en_us&edition=fundamental","pubTime":"2026-09-08 02:47","pubTimestamp":1788806848,"startTime":"0","endTime":"0","summary":"MILTON ESSEX S.A. ( ($PL:MTN) ) just unveiled an announcement. Milton Essex S.A., acting as sole shareholder of Sanford Biotech, has approved a PLN...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","SYNB","BK4581","IBB","GNOM","BK4585","CNCR","FBT","MTNmain","LFSC","IBBQ","TBXU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819175","title":"uniQure seeks accelerated approval for Huntington’s gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819175?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350375,"startTime":"0","endTime":"0","summary":"The latest update is out from uniQure ( ($QURE) ). On September 2, 2026, uniQure submitted a Biologics License Application to the U.S. Food and Dru...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/uniqure-seeks-accelerated-approval-for-huntingtons-gene-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/uniqure-seeks-accelerated-approval-for-huntingtons-gene-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBB","BK4585","CNCR","GNOM","SYNB","IBBQ","LFSC","TBXU","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856297","title":"Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856297","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856297?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354079/0/en/legend-biotech-to-participate-in-the-morgan-stanley-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","LU0029874061.USD","BK4137","BK4505","BK4585","IBB","GNOM","MEMS","SYNB","BK4581","XBI","MEDI","HCSG","LABU","XLV","BK4588","TBXU","LEGN","CNCR","BK4139","LFSC","FBT","CANC","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985383","title":"Novartis halts autoimmune CAR-T trials following three deaths, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985383?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258648,"startTime":"0","endTime":"0","summary":"Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after thr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","IE00BJJMRZ35.SGD","NVS","IE00B2B36J28.USD","BK4585","IE00B4R5TH58.HKD","MEDX","SYNB","BK4588","FBT","IE0002141913.USD","PPH","LU0208291251.USD","TBXU","GNOM","LFSC","NVIB","HYLG","LU0070302665.USD","IBB","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4578","LU0320765489.SGD","LU0211331839.USD","IBBQ","GDOC","IE0009355771.USD","BK4007","BMED","IDNA","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000711","title":"Circio boosts circVec gene therapy data and secures funding runway to 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000711","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000711?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:03","pubTimestamp":1788203022,"startTime":"0","endTime":"0","summary":"The latest update is out from Targovax ASA ( ($GB:0RIS) ). Circio Holding ASA reported that new preclinical data show its circVec circular RNA tech...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-boosts-circvec-gene-therapy-data-and-secures-funding-runway-to-2030?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-boosts-circvec-gene-therapy-data-and-secures-funding-runway-to-2030?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","LFSC","IBB","IBBQ","GNOM","BK4585","RNA","BK4588","TBXU","BK4139","FBT","IE0009354923.USD","SYNB","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760351","title":"Circio and Full Circles join forces on non-viral in vivo cell therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760351?lang=en_us&edition=fundamental","pubTime":"2026-08-26 13:43","pubTimestamp":1787723005,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) just unveiled an announcement. Circio Holding ASA and Full Circles Therapeutics have entered a research collaboration t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-and-full-circles-join-forces-on-non-viral-in-vivo-cell-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-and-full-circles-join-forces-on-non-viral-in-vivo-cell-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","CNCR","SYNB","GNOM","IBB","TBXU","FBT","BK4585","BK4588","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}